{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:09:53Z","timestamp":1790395793126,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","pediatric.theclinics.com","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.pcl.2017.08.014","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T22:18:46Z","timestamp":1511475526000},"page":"1403-1415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antiviral Drugs in Newborn and Children"],"prefix":"10.1016","volume":"64","author":[{"given":"Claudette L.","family":"Poole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Kimberlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pcl.2017.08.014_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003495-199447010-00009","article-title":"Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy","volume":"47","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.pcl.2017.08.014_bib2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00003495-199039040-00008","article-title":"Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections","volume":"39","author":"Faulds","year":"1990","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.pcl.2017.08.014_bib3","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pcl.2017.08.014_bib4","doi-asserted-by":"crossref","first-page":"449s","DOI":"10.1016\/S0248-8663(02)00659-8","article-title":"The interferons: pharmacology, mechanism of action, tolerance and side effects","volume":"23","author":"Arnaud","year":"2002","journal-title":"Rev Med Interne"},{"issue":"3","key":"10.1016\/j.pcl.2017.08.014_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jac\/37.3.403","article-title":"Antiviral resistance: mechanisms, clinical significance, and future implications","volume":"37","author":"Kimberlin","year":"1996","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"13","key":"10.1016\/j.pcl.2017.08.014_bib6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJM199709253371302","article-title":"Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group","volume":"337","author":"Hayden","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.pcl.2017.08.014_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/infdis\/jis765","article-title":"Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza","volume":"207","author":"Kimberlin","year":"2013","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.pcl.2017.08.014_bib8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.285.6.748","article-title":"Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial","volume":"285","author":"Welliver","year":"2001","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pcl.2017.08.014_bib9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1086\/381128","article-title":"Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis","volume":"189","author":"Hayden","year":"2004","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.pcl.2017.08.014_bib10","unstructured":"FDA. Oseltamivir [package insert]. 2004. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm147992.pdf."},{"key":"10.1016\/j.pcl.2017.08.014_bib11","unstructured":"Tamiflu (oseltamivir) \u2013 Safety Update on Neuropsychiatric Events; Review of Neuropsychiatric Events with other antiviral products 2007 November 9, 2007. Available at: https:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4325b_02_04_Tamiflu%20Adverse%20Event%20Review%202007.pdf."},{"issue":"5","key":"10.1016\/j.pcl.2017.08.014_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00006454-200005000-00005","article-title":"Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial","volume":"19","author":"Hedrick","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"18","key":"10.1016\/j.pcl.2017.08.014_bib13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1056\/NEJM200011023431801","article-title":"Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group","volume":"343","author":"Hayden","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2017.08.014_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003088-199936001-00003","article-title":"Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers","volume":"1","author":"Cass","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1016\/j.pcl.2017.08.014_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pcl.2017.08.014_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-199936001-00002","article-title":"Effect of renal impairment on the pharmacokinetics of intravenous zanamivir","volume":"1","author":"Cass","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.pcl.2017.08.014_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/rmed.1999.0718","article-title":"Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir","volume":"94","author":"Cass","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.pcl.2017.08.014_bib18","unstructured":"CDC Considerations Related to Investigational Use of Intravenous Zanamivir for 2016-2017 Influenza Season. 2016 November 3, 2016; Available at: https:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/intravenous-antivirals.htm. Accessed May 8, 2017."},{"key":"10.1016\/j.pcl.2017.08.014_bib19","doi-asserted-by":"crossref","unstructured":"Blumer J, Bradley JS, Romero JR, et\u00a0al. Safety, tolerability and pharmacokinetics (PK) of intravenous zanamivir (IVZ) treatment in hospitalized pediatric and adolescent patients with influenza: a phase II open-label, multicenter, single-arm study. IDWeek 2016 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), New Orleans, Louisiana, October 26-30, 2016; [abstract: 57391].","DOI":"10.1093\/ofid\/ofw194.26"},{"issue":"2","key":"10.1016\/j.pcl.2017.08.014_bib20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1542\/peds.108.2.230","article-title":"Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections","volume":"108","author":"Kimberlin","year":"2001","journal-title":"Pediatrics"},{"issue":"14","key":"10.1016\/j.pcl.2017.08.014_bib21","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa1003509","article-title":"Oral acyclovir suppression and neurodevelopment after neonatal herpes","volume":"365","author":"Kimberlin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.pcl.2017.08.014_bib22","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1542\/peds.2012-3216","article-title":"Guidance on management of asymptomatic neonates born to women with active genital herpes lesions","volume":"131","author":"Kimberlin","year":"2013","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.pcl.2017.08.014_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.7.1.1","article-title":"\u201cThe end of innocence\u201d revisited: resistance of herpesviruses to antiviral drugs","volume":"7","author":"Field","year":"1994","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.pcl.2017.08.014_bib24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0031-3955(16)38980-5","article-title":"Resistance to antivirals","volume":"42","author":"Laufer","year":"1995","journal-title":"Pediatr Clin North Am"},{"issue":"14","key":"10.1016\/j.pcl.2017.08.014_bib25","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1074\/jbc.M709530200","article-title":"Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase","volume":"283","author":"Lai","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.pcl.2017.08.014_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1086\/649212","article-title":"Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1\u00a0month through 11 years of age","volume":"50","author":"Kimberlin","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.pcl.2017.08.014_bib27","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jpeds.2015.01.023","article-title":"Intravenous acyclovir and renal dysfunction in children: a matched case control study","volume":"166","author":"Rao","year":"2015","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.pcl.2017.08.014_bib28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jpeds.2015.03.053","article-title":"Acyclovir dosing and acute kidney injury: deviations and direction","volume":"166","author":"Steinberg","year":"2015","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"10.1016\/j.pcl.2017.08.014_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003495-198223050-00001","article-title":"Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections","volume":"23","author":"Carmine","year":"1982","journal-title":"Drugs"},{"key":"10.1016\/j.pcl.2017.08.014_bib30","article-title":"Cytomegalovirus. Infectious diseases of the fetus and newborn infant","author":"Britt","year":"2011"},{"issue":"10","key":"10.1016\/j.pcl.2017.08.014_bib31","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.pcl.2017.08.014_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-199937020-00005","article-title":"Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers","volume":"37","author":"Brown","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.pcl.2017.08.014_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.pcl.2017.08.014_bib34","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy","volume":"17","author":"Rawlinson","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.pcl.2017.08.014_bib35","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1345\/aph.1A393","article-title":"Valganciclovir: an advance in cytomegalovirus therapeutics","volume":"36","author":"Cocohoba","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.pcl.2017.08.014_bib36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJM198601163140303","article-title":"Vidarabine versus acyclovir therapy in herpes simplex encephalitis","volume":"314","author":"Whitley","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2017.08.014_bib37","unstructured":"Aoki FY, Law BJ, Hammond GW, et\u00a0al. Acyclovir (ACV) suspension for treatment of acute herpes simplex virus (HSV) gingivostomatitis in children: a placebo(PL) controlled, double blind trial. in 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans (LA), October 17\u201320, 1993."},{"issue":"4","key":"10.1016\/j.pcl.2017.08.014_bib38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/AAC.37.4.619","article-title":"Antimicrobial strategies in the care of organ transplant recipients","volume":"37","author":"Rubin","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"4 Pt 1","key":"10.1016\/j.pcl.2017.08.014_bib39","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0022-3476(05)82495-3","article-title":"Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group","volume":"120","author":"Balfour","year":"1992","journal-title":"J\u00a0Pediatr"},{"issue":"22","key":"10.1016\/j.pcl.2017.08.014_bib40","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJM199111283252203","article-title":"A\u00a0controlled trial of acyclovir for chickenpox in normal children","volume":"325","author":"Dunkle","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.pcl.2017.08.014_bib41","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/infdis\/165.3.450","article-title":"Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group","volume":"165","author":"Whitley","year":"1992","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.pcl.2017.08.014_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/infdis\/157.2.309","article-title":"Acyclovir prevents dissemination of varicella in immunocompromised children","volume":"157","author":"Nyerges","year":"1988","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.pcl.2017.08.014_bib43","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood.V67.4.1162.1162","article-title":"Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease","volume":"67","author":"Miller","year":"1986","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pcl.2017.08.014_bib44","first-page":"S1","article-title":"Overview of cytomegalovirus infections in HIV-infected patients: current therapies and future strategies","volume":"4","author":"Crumpacker","year":"1991","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"2A","key":"10.1016\/j.pcl.2017.08.014_bib45","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/0002-9343(92)90329-A","article-title":"Mechanism of action of foscarnet against viral polymerases","volume":"92","author":"Crumpacker","year":"1992","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.pcl.2017.08.014_bib46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000167987","article-title":"Foscarnet nephrotoxicity: mechanism, incidence and prevention","volume":"9","author":"Deray","year":"1989","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1016\/j.pcl.2017.08.014_bib47","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1210\/jcem-72-5-1130","article-title":"Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism","volume":"72","author":"Jacobson","year":"1991","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.pcl.2017.08.014_bib48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7326\/0003-4819-115-9-665","article-title":"A\u00a0randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS","volume":"115","author":"Palestine","year":"1991","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.pcl.2017.08.014_bib49","first-page":"254","article-title":"Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections","volume":"7","author":"Balfour","year":"1994","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.pcl.2017.08.014_bib50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.pcl.2017.08.014_bib51","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in\u00a0vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.pcl.2017.08.014_bib52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/rmv.589","article-title":"Clinical features and treatment of adenovirus infections","volume":"18","author":"Lenaerts","year":"2008","journal-title":"Rev Med Virol"},{"issue":"7","key":"10.1016\/j.pcl.2017.08.014_bib53","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/00007890-200210150-00027","article-title":"Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient","volume":"74","author":"Carter","year":"2002","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.pcl.2017.08.014_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00007890-200301150-00020","article-title":"Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults","volume":"75","author":"Vats","year":"2003","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.pcl.2017.08.014_bib55","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1034\/j.1600-6143.2003.30202.x","article-title":"Treatment of refractory BK virus-associated nephropathy with cidofovir","volume":"3","author":"Kadambi","year":"2003","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.pcl.2017.08.014_bib56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0026-895X(25)08828-5","article-title":"Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine","volume":"41","author":"Ho","year":"1992","journal-title":"Mol Pharmacol"},{"issue":"8","key":"10.1016\/j.pcl.2017.08.014_bib57","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1128\/AAC.35.8.1596","article-title":"Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice","volume":"35","author":"Yang","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.pcl.2017.08.014_bib58","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1128\/AAC.39.6.1247","article-title":"Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients","volume":"39","author":"Cundy","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.pcl.2017.08.014_bib59","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/infdis\/171.4.788","article-title":"(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I\/II study of a novel antiviral nucleotide analogue","volume":"171","author":"Lalezari","year":"1995","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.pcl.2017.08.014_bib60","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/infdis\/170.3.570","article-title":"Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS","volume":"170","author":"Lalezari","year":"1994","journal-title":"J\u00a0Infect Dis"},{"issue":"Suppl 6","key":"10.1016\/j.pcl.2017.08.014_bib61","first-page":"S5","article-title":"Treatment of hepatitis B and C in children","volume":"14","author":"El-Shabrawi","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.pcl.2017.08.014_bib62","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s40262-016-0397-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of ledipasvir\/sofosbuvir, a fixed-dose combination tablet for the treatment of hepatitis C","volume":"55","author":"German","year":"2016","journal-title":"Clin Pharmacokinet"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395517301177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395517301177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:07:51Z","timestamp":1751029671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395517301177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0031395517301177"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2017.08.014","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral Drugs in Newborn and Children","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2017.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}